460 related articles for article (PubMed ID: 34398969)
21. Comparison of Colorectal and Endometrial Microsatellite Instability Tumor Analysis and Premm
Mannucci A; Furniss CS; Ukaegbu C; Horiguchi M; Fehlmann T; Uno H; Yurgelun MB; Syngal S
J Clin Oncol; 2020 Dec; 38(34):4086-4094. PubMed ID: 32997573
[TBL] [Abstract][Full Text] [Related]
22. A retrospective study of consistency between immunohistochemistry and polymerase chain reaction of microsatellite instability in endometrial cancer.
Wang C; Kuang W; Zeng J; Ren Y; Liu Q; Sun H; Feng M; Liang D
PeerJ; 2023; 11():e15920. PubMed ID: 37663290
[TBL] [Abstract][Full Text] [Related]
23. Strategies for Lynch syndrome identification in selected and unselected gynecological cancers.
Carnevali I; Sahnane N; Chiaravalli AM; Di Lauro E; Facco C; Facchi S; Casarin J; Ghezzi F; Sessa F; Tibiletti MG
Eur J Cancer Prev; 2022 Jul; 31(4):369-376. PubMed ID: 34519692
[TBL] [Abstract][Full Text] [Related]
24. Lynch syndrome-associated endometrial carcinoma with MLH1 germline mutation and MLH1 promoter hypermethylation: a case report and literature review.
Yokoyama T; Takehara K; Sugimoto N; Kaneko K; Fujimoto E; Okazawa-Sakai M; Okame S; Shiroyama Y; Yokoyama T; Teramoto N; Ohsumi S; Saito S; Imai K; Sugano K
BMC Cancer; 2018 May; 18(1):576. PubMed ID: 29783979
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer.
Hodan R; Kingham K; Cotter K; Folkins AK; Kurian AW; Ford JM; Longacre T
Cancer Med; 2021 Feb; 10(3):1012-1017. PubMed ID: 33369189
[TBL] [Abstract][Full Text] [Related]
26. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.
Latham A; Srinivasan P; Kemel Y; Shia J; Bandlamudi C; Mandelker D; Middha S; Hechtman J; Zehir A; Dubard-Gault M; Tran C; Stewart C; Sheehan M; Penson A; DeLair D; Yaeger R; Vijai J; Mukherjee S; Galle J; Dickson MA; Janjigian Y; O'Reilly EM; Segal N; Saltz LB; Reidy-Lagunes D; Varghese AM; Bajorin D; Carlo MI; Cadoo K; Walsh MF; Weiser M; Aguilar JG; Klimstra DS; Diaz LA; Baselga J; Zhang L; Ladanyi M; Hyman DM; Solit DB; Robson ME; Taylor BS; Offit K; Berger MF; Stadler ZK
J Clin Oncol; 2019 Feb; 37(4):286-295. PubMed ID: 30376427
[TBL] [Abstract][Full Text] [Related]
27. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities.
Garg K; Leitao MM; Kauff ND; Hansen J; Kosarin K; Shia J; Soslow RA
Am J Surg Pathol; 2009 Jun; 33(6):925-33. PubMed ID: 19238076
[TBL] [Abstract][Full Text] [Related]
28. Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing.
Ferguson SE; Aronson M; Pollett A; Eiriksson LR; Oza AM; Gallinger S; Lerner-Ellis J; Alvandi Z; Bernardini MQ; MacKay HJ; Mojtahedi G; Tone AA; Massey C; Clarke BA
Cancer; 2014 Dec; 120(24):3932-9. PubMed ID: 25081409
[TBL] [Abstract][Full Text] [Related]
29. Universal Screening for Mismatch-Repair Deficiency in Endometrial Cancers to Identify Patients With Lynch Syndrome and Lynch-like Syndrome.
Watkins JC; Yang EJ; Muto MG; Feltmate CM; Berkowitz RS; Horowitz NS; Syngal S; Yurgelun MB; Chittenden A; Hornick JL; Crum CP; Sholl LM; Howitt BE
Int J Gynecol Pathol; 2017 Mar; 36(2):115-127. PubMed ID: 27556954
[TBL] [Abstract][Full Text] [Related]
30. Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?
Kahn RM; Gordhandas S; Maddy BP; Baltich Nelson B; Askin G; Christos PJ; Caputo TA; Chapman-Davis E; Holcomb K; Frey MK
Cancer; 2019 Sep; 125(18):3172-3183. PubMed ID: 31150123
[TBL] [Abstract][Full Text] [Related]
31. Isolated Loss of PMS2 Immunohistochemical Expression is Frequently Caused by Heterogenous MLH1 Promoter Hypermethylation in Lynch Syndrome Screening for Endometrial Cancer Patients.
Kato A; Sato N; Sugawara T; Takahashi K; Kito M; Makino K; Sato T; Shimizu D; Shirasawa H; Miura H; Sato W; Kumazawa Y; Sato A; Kumagai J; Terada Y
Am J Surg Pathol; 2016 Jun; 40(6):770-6. PubMed ID: 26848797
[TBL] [Abstract][Full Text] [Related]
32. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
Jin W; Wang LQ; Liu Y; Liu AJ
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
[No Abstract] [Full Text] [Related]
33. Screening for germline mutations of MLH1, MSH2, MSH6 and PMS2 genes in Slovenian colorectal cancer patients: implications for a population specific detection strategy of Lynch syndrome.
Berginc G; Bracko M; Ravnik-Glavac M; Glavac D
Fam Cancer; 2009; 8(4):421-9. PubMed ID: 19526325
[TBL] [Abstract][Full Text] [Related]
34. Germline mismatch repair gene variants analyzed by universal sequencing in Japanese cancer patients.
Kiyozumi Y; Matsubayashi H; Horiuchi Y; Higashigawa S; Oishi T; Abe M; Ohnami S; Urakami K; Nagashima T; Kusuhara M; Miyake H; Yamaguchi K
Cancer Med; 2019 Sep; 8(12):5534-5543. PubMed ID: 31386297
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens.
Chapel DB; Yamada SD; Cowan M; Lastra RR
Gynecol Oncol; 2018 Jun; 149(3):570-574. PubMed ID: 29656794
[TBL] [Abstract][Full Text] [Related]
36. The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis.
Ryan NAJ; Glaire MA; Blake D; Cabrera-Dandy M; Evans DG; Crosbie EJ
Genet Med; 2019 Oct; 21(10):2167-2180. PubMed ID: 31086306
[TBL] [Abstract][Full Text] [Related]
37. Mismatch repair deficiency testing in clinical practice.
Buza N; Ziai J; Hui P
Expert Rev Mol Diagn; 2016; 16(5):591-604. PubMed ID: 26895074
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of Lynch syndrome among patients with newly diagnosed endometrial cancers.
Egoavil C; Alenda C; Castillejo A; Paya A; Peiro G; Sánchez-Heras AB; Castillejo MI; Rojas E; Barberá VM; Cigüenza S; Lopez JA; Piñero O; Román MJ; Martínez-Escoriza JC; Guarinos C; Perez-Carbonell L; Aranda FI; Soto JL
PLoS One; 2013; 8(11):e79737. PubMed ID: 24244552
[TBL] [Abstract][Full Text] [Related]
39. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
[TBL] [Abstract][Full Text] [Related]
40. An Analysis of Clinical, Surgical, Pathological and Molecular Characteristics of Endometrial Cancer According to Mismatch Repair Status. A Multidisciplinary Approach.
Dondi G; Coluccelli S; De Leo A; Ferrari S; Gruppioni E; Bovicelli A; Godino L; Coadă CA; Morganti AG; Giordano A; Santini D; Ceccarelli C; Turchetti D; De Iaco P; Perrone AM
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
